5-Amino-1MQ Peptide: What It Is and What Research Has Examined

What Is 5-Amino-1MQ?

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in NAD+ metabolism and cellular energy regulation. The compound — formally 5-amino-1-methylquinolinium — belongs to a class of methylquinolinium derivatives developed to selectively block NNMT activity. Research has examined it primarily in the context of metabolic disease, obesity, and cancer biology, with most published evidence coming from preclinical animal models and in vitro cell-line work.

---

What Is 5-Amino-1MQ Studied For?

Research on 5-Amino-1MQ goes back to 2021 — 5 years — with studies continuing through 2024.

1. Adiposity and Weight Reduction — A 2022 preclinical study in diet-induced obese (DIO) mice reported that combining 5-amino-1-methylquinolinium with a low-fat diet produced dramatic whole-body adiposity and weight loss, rapidly normalizing body composition measures to levels comparable to age-matched lean controls, an outcome that the low-fat diet switch alone could not achieve in the same timeframe.

2. Gut Microbiome Remodeling — The same 2022 DIO mouse study found that the combination of NNMT inhibition and caloric restriction established a distinct gut microbiome profile, suggesting the compound's metabolic effects may intersect with microbial community composition, though the mechanistic link remains uncharacterized in that work.

3. Anti-Proliferative Activity in Cancer Cells — A 2021 in vitro study tested 5MQ — a closely related methylquinolinium NNMT inhibitor — across a concentration range of 0.1–500 µM on HeLa epithelial cervical cancer cells, reporting dose-dependent anti-proliferative effects, establishing proof-of-concept for this compound class against a human cancer cell line.

4. Tumor Progression and Immunotherapy Resistance — A 2024 preclinical study in urothelial bladder cancer models examined NNMT expression in cancer-associated fibroblasts, finding that NNMT activity in that cellular compartment drives tumor progression and modulates macrophage behavior in ways that reduce immunotherapy efficacy, positioning NNMT inhibition as a potential strategy to improve treatment response.

No human clinical trials of 5-Amino-1MQ have been published in this literature pool. The available human-adjacent data comes from in vitro work on human cell lines — not from trials enrolling human participants.

---

How Does 5-Amino-1MQ Work?

5-Amino-1MQ works by blocking NNMT, an enzyme that methylates nicotinamide using S-adenosylmethionine (SAM) as the methyl donor. When NNMT is active, it consumes SAM and produces 1-methylnicotinamide as a byproduct, effectively diverting methyl groups away from other metabolic processes and reducing NAD+ precursor availability. By inhibiting this enzyme, 5-Amino-1MQ shifts the cellular methyl donor pool and supports NAD+ precursor recycling through the salvage pathway.

In adipose tissue specifically, elevated NNMT activity has been associated with increased fat storage and impaired energy expenditure. Blocking NNMT in that context is hypothesized to restore metabolic flexibility — a rationale consistent with the weight and adiposity findings reported in the 2022 DIO mouse study. In tumor biology, NNMT expression in cancer-associated fibroblasts appears to influence the surrounding immune microenvironment, particularly macrophage polarization, which the 2024 bladder cancer preclinical study examined through single-cell transcriptomic analysis and immunohistochemical approaches.

The compound's selectivity for NNMT over other methyltransferases is part of what distinguishes it from broader SAM-pathway modulators, though the specificity profile across the full methyltransferase family has not been exhaustively characterized in the available published literature.

---

What Does Animal Research Show?

The most detailed preclinical findings come from the 2022 study published in Scientific Reports, which used diet-induced obese mice as its model. The study combined 5-amino-1-methylquinolinium treatment with a low-fat dietary switch and compared outcomes against a low-fat diet switch alone. Animals receiving the NNMT inhibitor alongside dietary modification showed rapid normalization of whole-body adiposity and body weight to levels seen in age-matched lean controls. The diet-only group did not reach equivalent normalization within the same period.

Beyond body composition, that study characterized the gut microbiome of treated animals and found that NNMT inhibition combined with reduced caloric intake produced a distinct microbial community profile — one that differed from both the obese control group and the diet-only group. The specific bacterial taxa driving that shift and whether they contribute causally to the metabolic outcomes observed were not resolved within the study's scope.

The 2024 study in Journal for Immunotherapy of Cancer used preclinical bladder cancer models to examine NNMT's role in cancer-associated fibroblasts (CAFs). Using single-cell transcriptomic analyses, the investigators identified NNMT expression as a driver of tumor progression and a mediator of immunotherapy resistance. The mechanism centered on CAF-derived NNMT activity shaping the macrophage population within the tumor microenvironment. While this study focused on NNMT biology rather than 5-Amino-1MQ specifically, it provides direct mechanistic rationale for why an NNMT inhibitor of this class is under investigation in oncology contexts.

---

What Does In Vitro Research Show?

The 2021 study published in the Journal of Obstetrics and Gynaecology tested 5MQ — a methylquinolinium NNMT inhibitor in the same compound class as 5-Amino-1MQ — on HeLa cells, a well-characterized human cervical cancer cell line. The investigators applied concentrations ranging from 0.1 to 500 µM and observed dose-dependent reductions in cell viability and proliferation. The study framed this as an initial investigation, noting that anti-proliferative effects of 5MQ on cervical cancer cells had not been previously reported.

This work establishes proof-of-concept that NNMT inhibition using a methylquinolinium compound can suppress growth in a human cancer cell line under laboratory conditions. However, in vitro cell-line results do not predict clinical outcomes — HeLa cells represent a single cancer type tested in isolation, without the immune system, stromal environment, or pharmacokinetic variables present in a living organism. The concentration range used (up to 500 µM) is also substantially higher than what would typically be achievable in tissue through systemic administration, a practical constraint the study does not address.

---

What Is Still Unknown About 5-Amino-1MQ?

The literature base for 5-Amino-1MQ is small. Three studies span the available evidence: two in animal or preclinical models and one in a human cancer cell line. That pool supports several mechanistic hypotheses — NNMT inhibition affecting adiposity, gut microbiota, and tumor microenvironments — but leaves a number of fundamental questions unanswered.

No published human clinical trials exist for 5-Amino-1MQ. Pharmacokinetics, bioavailability, tissue distribution, and safety in humans have not been reported in peer-reviewed literature. The gut microbiome changes observed in DIO mice have not been characterized well enough to determine whether they are a cause or consequence of metabolic improvement, or whether they replicate in other species or dietary contexts.

In oncology, the 2024 bladder cancer study documents NNMT's role in shaping the tumor immune microenvironment but does not test NNMT inhibition as a therapeutic intervention — it characterizes the pathway, not the treatment outcome. Translating that mechanistic insight into an interventional study using 5-Amino-1MQ or a related inhibitor remains a future research question.

The selectivity of 5-Amino-1MQ across the broader methyltransferase family, its off-target profile, and its behavior across different cancer subtypes or metabolic disease states are all areas where published data are absent. Research interest in NNMT biology is growing — as reflected by the span of studies from 2021 to 2024 — but the compound-specific evidence base remains early-stage.

---

Where Can I Buy 5-Amino-1MQ?

5-Amino-1MQ is available for purchase from BioMax Research at biomaxresearch.com. BioMax Research is a highly regarded source for research peptides, with every product third-party lab tested and backed by a verifiable certificate of analysis (COA).

---